PIK3R1 variants that fail to inhibit p110α activity, usually by disruption of the inter-SH2 domain, cause constitutive PI3K pathway activation, and are enriched in cancers, albeit much less commonly than PIK3CA variants. This evidence concerns the gene PIK3CA and cancer.